At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMPS COMPASS Pathways plc
Pre-Mkt 10-16 07:42:37 EDT
11.62
+0.35
+3.11%
盘前11.70
+0.08+0.69%
07:11 EDT
High11.70Low11.15Vol2.81M
Open11.25D1 Closing11.27Amplitude4.84%
Mkt Cap1.60BTradable Cap1.24BTotal Shares138.00M
T/O32.12MT/O Rate2.62%Tradable Shares107.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cathie Wood’s ARK Investment buys 284K shares of Compass Pathways today
TIPRANKS  ·  10-13
Cathie Wood’s ARK Investment buys 284K shares of Compass Pathways today
Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-02
Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Compass Pathways Names Kelley Boucher Chief People Officer
Reuters  ·  09-30
Compass Pathways Names Kelley Boucher Chief People Officer
H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
TIPRANKS  ·  09-22
H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Compass Pathways Joins TD Cowen Novel Mechanisms in Neuropsychiatry Summit Fireside Chat
Reuters  ·  09-16
Compass Pathways Joins TD Cowen Novel Mechanisms in Neuropsychiatry Summit Fireside Chat
As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards
Reuters  ·  09-15
As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards
Compass Pathways Launches ‘Change the Tune in Trd’ in the U.S. to Advance Hcp Understanding of Treatment-Resistant Depression at Psych Congress 2026
THOMSON REUTERS  ·  09-15
Compass Pathways Launches ‘Change the Tune in Trd’ in the U.S. to Advance Hcp Understanding of Treatment-Resistant Depression at Psych Congress 2026
Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs
Reuters  ·  09-15
Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs
FDA to Hold Public Hearing on Psychedelic Drugs as Trump-Driven Push Gathers Pace
Reuters  ·  09-15
FDA to Hold Public Hearing on Psychedelic Drugs as Trump-Driven Push Gathers Pace
Strata Mental Health Solutions awarded training grant by Compass Pathways
TIPRANKS  ·  09-12
Strata Mental Health Solutions awarded training grant by Compass Pathways
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training
THOMSON REUTERS  ·  09-10
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training
Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14
Reuters  ·  09-10
Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14
U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs
Reuters  ·  09-10
U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software
Reuters  ·  09-09
U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software
Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug
Reuters  ·  09-09
Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year
THOMSON REUTERS  ·  09-09
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year
Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4
THOMSON REUTERS  ·  09-09
Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4
Compass Pathways - Continue to Expect Commercial Launch in H1 2027
THOMSON REUTERS  ·  09-09
Compass Pathways - Continue to Expect Commercial Launch in H1 2027
Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings
THOMSON REUTERS  ·  09-09
Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings
Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year
THOMSON REUTERS  ·  09-09
Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year

Introduction

Company Name.
COMPASS Pathways plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Issue price:
--